Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020 (Related Reports)

Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020


February 29, 2012
438 Pages - SKU: GBDT3865603
License type:
Online Download      US $6,995.00
Global Site License      US $20,985.00
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014
4/15/2014 | published by: GlobalData
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014 provides data on the  |  read more...
$2,500.00
Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014
4/15/2014 | published by: GlobalData
Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014 provides data on the Metastatic Ovarian Cancer clinical trial scenario. This report provides elemental  |  read more...
$2,500.00
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014
4/15/2014 | published by: GlobalData
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014 provides data on the Metastatic Transitional  |  read more...
$2,500.00
Natural Killer Cell Lymphomas Global Clinical Trials Review, H1, 2014
4/15/2014 | published by: GlobalData
Natural Killer Cell Lymphomas Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Natural Killer Cell Lymphomas Global Clinical Trials Review, H1, 2014 provides data on the Natural Killer Cell Lymphomas clinical trial scenario. This  |  read more...
$2,500.00
Oral Cavity (Mouth) Cancer Global Clinical Trials Review, H1, 2014
4/15/2014 | published by: GlobalData
Oral Cavity (Mouth) Cancer Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Oral Cavity (Mouth) Cancer Global Clinical Trials Review, H1, 2014 provides data on the Oral Cavity (Mouth) Cancer clinical trial scenario. This  |  read more...
$2,500.00
Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2014
4/15/2014 | published by: GlobalData
Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2014 provides data on the Recurrent Malignant Glioma clinical trial scenario. This report provides elemental  |  read more...
$2,500.00
Refractory Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2014
4/15/2014 | published by: GlobalData
Refractory Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Refractory Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2014 provides data on the Refractory Acute Myeloid Leukemia clinical trial scenario. This  |  read more...
$2,500.00
Refractory Leukemia Global Clinical Trials Review, H1, 2014
4/15/2014 | published by: GlobalData
Refractory Leukemia Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Refractory Leukemia Global Clinical Trials Review, H1, 2014 provides data on the Refractory Leukemia clinical trial scenario. This report provides elemental information and data  |  read more...
$2,500.00
Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2014
4/15/2014 | published by: GlobalData
Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2014 provides data on the Refractory Multiple Myeloma clinical trial scenario. This report provides elemental  |  read more...
$2,500.00
Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 - Early Stage Pipeline Shows Diversity of Novel Targets though Commercial Impact Remains Distant
4/14/2014 | published by: GBI Research
Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 - Early Stage Pipeline Shows Diversity of Novel Targets though Commercial Impact Remains Distant Summary GBI Research, the leading business intelligence provider, has released its latest research,‘Pancreatic Adenocarcinoma  |  read more...
$3,500.00